Loading provider…
Loading provider…
Hematology & Oncology Physician in Niles, IL
NPI: 1255328878Primary Employer
Illinois Cancer Specialists
illinoiscancerspecialists.com
HQ Phone
Get Leonard's Phone NumberMobile
Get Leonard's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardIL State Medical License
CA State Medical License
1979
IL State Medical License
1982 - 2026
TX State Medical License
1977 - 1982

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
Jacobs School of Medicine and Biomedical Sciences
medicine.buffalo.edu
Medical School
Until 1975
City of Hope National Medical Center
Fellowship • Hematology and Medical Oncology
1979 - 1982
Washington University/B-JH/SLCH Consortium
Fellowship • Hematology and Medical Oncology
1978 - 1979
University of Texas Southwestern Medical Center
Residency • Internal Medicine
1975 - 1978
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 124 | 326 |
| 2 | 99213Established patient office or other outpatient visit, typically 15 minutes | 69 | 86 |
| 3 | 99215Established patient office or other outpatient, visit typically 40 minutes | 41 | 78 |
| 4 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 37 | 90 |
| 5 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 36 | 145 |
Authors: Cary Presant
Journal: Cancer Treat Rep
Authors: Cary Presant
Journal: Cancer Res
Phase I and preliminary phase II observations of high-dose intermittent 6-thioguanine.
Authors: Cary Presant
Journal: Cancer Treat Rep
Lead Sponsor: Novartis Pharmaceuticals
Intervention / Treatment: DRUG: Imatinib, DRUG: Bosutinib, DRUG: Nilotinib, DRUG: Dasatinib, DRUG: Asciminib
Lead Sponsor: Incyte Corporation
Intervention / Treatment: DRUG: Placebo, DRUG: Prednisone, DRUG: Methylprednisolone, DRUG: Itacitinib
Lead Sponsor: GlaxoSmithKline
Intervention / Treatment: DRUG: Dexamethasone, DRUG: Daratumumab, DRUG: Bortezomib, DRUG: Belantamab mafodotin